Enibarcimab for the treatment of septic shock in patients selected by a combination of the biomarkers bio-ADM and DPP3: A prespecified subgroup analysis of the AdrenOSS-2 trial

  • J Crit Care. 2025 Aug:88:155077. doi: 10.1016/j.jcrc.2025.155077.
Claudia Knothe  1 ,  Stephan Witte  1 ,  Andreas Bergmann  2 ,  Alexandre Mebazaa  3 ,  Pierre-Francois Laterre  4 ,  Peter Pickkers  5 ,  ADRENOSS-2 Investigators
Affiliations
  • 1. Adrenomed AG, Neuendorfstr. 15a, 16761 Hennigsdorf, Germany.
  • 2. 4Teen4, Neuendorfstrasse 15A, 16761 Hennigsdorf, Germany.
  • 3. Département d'Anesthésie-Réanimation, Hôpital Lariboisière, 2 Rue A Paré, 75010 Paris, France.
  • 4. Cliniques Universitaires Saint-Luc, (UCL Bruxelles), Avenue Hippocrate 10, 1200 Brussels, Belgium.
  • 5. Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. Electronic address: [email protected].
PMID: 40215573 DOI: 10.1016/j.jcrc.2025.155077
Products